Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Natural Products for the Treatment of Obesity
share announcement

Special Issue "Natural Products for the Treatment of Obesity"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: closed (15 June 2023) | Viewed by 2918

Special Issue Editors

Dr. Diego A. Luna-Vital

E-Mail Website
Guest Editor
The Institute for Obesity Research, Tecnologico de Monterrey, Monterrey 64849, Mexico
Interests: obesity; inflammation; cancer; polyphenols; natural colorants; anthocyanins; peptides
Special Issues, Collections and Topics in MDPI journals
Dr. Luis Mojica

E-Mail Website
Guest Editor
Tecnología Alimentaria, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, A. C., CIATEJ, Unidad Zapopan, Camino Arenero 1227, El Bajío, Zapopan 45019, Mexico
Interests: obesity; polyphenols; novel food ingredients; alternative proteins
Dr. Astrid Domínguez-Uscanga

E-Mail
Guest Editor
The Institute for Obesity Research, Tecnológico de Monterrey, Av. Eugenio Garza Sada 2501 Sur, Monterrey 64849, Mexico
Interests: obesity; dyslipidemia; bioactive compounds; polyphenols

Special Issue Information

Dear Colleagues,

Changes in dietary habits, especially in the consumption of high-fat, high-sugar and high-salt foods, have increased the prevalence of several health conditions, including obesity. According to the World Health Organization, obesity has nearly tripled since 1975; in 2016, more than 1.9 billion adults were overweight, and over 650 million of this number were obese. Additionally, 39 million children under the age of 5 were overweight or obese in 2020. Physiologically, obesity is defined as an abnormal accumulation of adipose tissue within the body that carries out a subclinical chronic state of inflammation. This condition is known to be closely related to the onset of comorbidities, including insulin resistance, diabetes, hypertension, dyslipidemia, etc. The growing association between plant-derived food and its effect in reducing the risk of noncommunicable diseases has opened doors for wide range of research focused on the chemical characterization of natural compounds and their potential health benefits. Anti-obesity natural compounds have been reported, including those extracted from plants (polyphenols, alkaloids, nortriterpen quinones, carotenoids, bioactive peptides, etc.), products from microbial sources (lipstatin, gut microbiota, probiotic bacteria), and compounds from marine organisms (polyacetylenic acids, sesquiterpene quinones, dihydroxyanthraquinones, etc). However, there is still a need to address important aspects of the use of natural compounds in obesity, for instance, chemical characterization and stabilization, effective dosing, mechanisms of action, etc.

This Special Issue invites both reviews and original articles that elucidate recent research progress in natural products that serve as drug candidates or adjuvants in the treatment of obesity. Topics include but are not limited to natural products and obesity-related comorbidities, chemical characterization, anti-obesity mechanisms of action in natural products, chemical characterizations, the pre-clinical and clinical evaluation of natural compounds in obesity, and functional food development incorporating anti-obesity natural compounds. A collection of high-quality manuscripts on these topics will be published in this Special Issue of Pharmaceuticals.

Dr. Diego A. Luna-Vital
Dr. Luis Mojica
Dr. Astrid Domínguez-Uscanga
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • natural compounds
  • obesity
  • polyphenols
  • molecular nutrition
  • metabolic diseases
  • inflammation

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

get_app
Article
In Silico Identification of Peptides with PPARγ Antagonism in Protein Hydrolysate from Rice (Oryza sativa)
by
Felipe de Jesús Ruiz-López
,
Bryan Alejandro Espinosa-Rodríguez
,
David Arturo Silva-Mares
,
Blanca Edelia González-Martínez
,
Manuel López-Cabanillas Lomelí
,
Luis Fernando Méndez-López
and
Jesús Alberto Vázquez-Rodríguez
Pharmaceuticals 2023, 16(3), 440; https://doi.org/10.3390/ph16030440 - 15 Mar 2023
Cited by 1 | Viewed by 1103
Abstract
At least half the population in industrialized countries suffers from obesity due to excessive accumulation of adipose tissue. Recently, rice (Oryza sativa) proteins have been considered valuable sources of bioactive peptides with antiadipogenic potential. In this study, the digestibility and bioaccessibility [...] Read more.
At least half the population in industrialized countries suffers from obesity due to excessive accumulation of adipose tissue. Recently, rice (Oryza sativa) proteins have been considered valuable sources of bioactive peptides with antiadipogenic potential. In this study, the digestibility and bioaccessibility in vitro of a novel protein concentrate (NPC) from rice were determined through INFOGEST protocols. Furthermore, the presence of prolamin and glutelin was evaluated via SDS-PAGE, and their potential digestibility and the bioactivity of ligands against peroxisome proliferator-activated receptor gamma (PPARγ) were explored by BIOPEP UWM and HPEPDOCK. For the top candidates, molecular simulations were conducted using Autodock Vina to evaluate their binding affinity against the antiadipogenic region of PPARγ and their pharmacokinetics and drug-likeness using SwissADME. Simulating gastrointestinal digestion showed a recovery of 43.07% and 35.92% bioaccessibility. The protein banding patterns showed the presence of prolamin (57 kDa) and glutelin (12 kDa) as the predominant proteins in the NPC. The in silico hydrolysis predicts the presence of three and two peptide ligands in glutelin and prolamin fraction, respectively, with high affinity for PPARγ (≤160). Finally, the docking studies suggest that the prolamin-derived peptides QSPVF and QPY (−6.38 & −5.61 kcal/mol, respectively) have expected affinity and pharmacokinetic properties to act as potential PPARγ antagonists. Hence, according to our results, bioactive peptides resulting from NPC rice consumption might have an antiadipogenic effect via PPARγ interactions, but further experimentation and validation in suitable biological model systems are necessary to gain more insight and to provide evidence to support our in silico findings. Full article
(This article belongs to the Special Issue Natural Products for the Treatment of Obesity)
►▼ Show Figures

Figure 1

get_app
Article
West Mexico Berries Modulate α-Amylase, α-Glucosidase and Pancreatic Lipase Using In Vitro and In Silico Approaches
by
Carmen Alejandrina Virgen-Carrillo
,
Elia Herminia Valdés Miramontes
,
David Fonseca Hernández
,
Diego A. Luna-Vital
and
Luis Mojica
Pharmaceuticals 2022, 15(9), 1081; https://doi.org/10.3390/ph15091081 - 30 Aug 2022
Cited by 3 | Viewed by 1303
Abstract
The objective was to evaluate the antioxidant and biological potential of eight freeze-dried berry varieties of southern Jalisco using in silico and in vitro approaches. Fourteen tentative phenolic compounds were identified in berries by ESI-QToF, including anthocyanins, phenolic acids, flavanols and flavonols. In [...] Read more.
The objective was to evaluate the antioxidant and biological potential of eight freeze-dried berry varieties of southern Jalisco using in silico and in vitro approaches. Fourteen tentative phenolic compounds were identified in berries by ESI-QToF, including anthocyanins, phenolic acids, flavanols and flavonols. In silico assays of phytochemicals in the berry inhibiting enzymes related to obesity and diabetes showed predicted binding energy interactions (ranging from −5.4 to −9.3 kcal/mol). Among the cultivars, antioxidant potential for DPPH IC50 ranged from 1.27 to 3.40 mg/mL, ABTS IC50 from 2.26 to 7.32 mg/mL and nitric oxide (NO) inhibition IC50 from 4.26 to 11.07 mg/mL. The potential to inhibit α-amylase IC50 ranged from 4.02 to 7.66 mg/mL, α-glucosidase IC50 from 0.27 to 4.09 mg/mL, lipase IC50 from 1.30 to 4.82 mg/mL and DPP-IV IC50 from 1.36 to 3.31 mg/mL. Blackberry cultivars from the southern Jalisco region showed outstanding biological potential compared to other evaluated berries and could be used in the formulation of functional foods in the prevention of noncommunicable diseases. Full article
(This article belongs to the Special Issue Natural Products for the Treatment of Obesity)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop